Eli Lilly and Company (LLY)

US — Healthcare Sector
Peers: JNJ  BMY  ABBV  PFE  MRK  AMGN  GILD 

Automate Your Wheel Strategy on LLY

With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LLY
  • Rev/Share 54.5268
  • Book/Share 17.633
  • PB 44.8598
  • Debt/Equity 2.4432
  • CurrentRatio 1.3723
  • ROIC 0.2572

 

  • MktCap 745792413120.0
  • FreeCF/Share 0.5421
  • PFCF 1530.7726
  • PE 63.6754
  • Debt/Assets 0.4309
  • DivYield 0.0071
  • ROE 0.7692

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade LLY Erste Group Buy Hold -- -- June 5, 2025
Downgrade LLY HSBC Securities Buy Reduce $1150 $700 April 28, 2025
Initiation LLY Cantor Fitzgerald -- Overweight -- $975 April 22, 2025
Resumed LLY BofA Securities -- Buy -- $997 Dec. 10, 2024
Initiation LLY Bernstein -- Outperform -- $1100 Oct. 17, 2024
Resumed LLY Citigroup -- Buy -- $1060 Sept. 13, 2024

News

Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
LLY
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Read More
image for news Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
BSX, LLY
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Read More
image for news These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
LLY
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive

Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable growth prospects and strong positioning in the obesity and diabetes markets. The bank made only minor adjustments to its revenue and earnings estimates through 2026, driven primarily by higher sales expectations for weight-loss drug Zepbound.

Read More
image for news Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
ABBV, JNJ, LLY
Published: July 08, 2025 by: CNBC
Sentiment: Neutral

President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.

Read More
image for news Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
LLY
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Read More
image for news Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
LLY
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

Read More
image for news Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
LLY
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
CVS drops Lilly's Zepbound
CVS, LLY
Published: July 01, 2025 by: CNBC Television
Sentiment: Negative

CNBC's Angelica Peebles reports on news regarding CVS.

Read More
image for news CVS drops Lilly's Zepbound
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
LLY
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
LLY, NVO
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive

Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.

Read More
image for news NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
LLY
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.

Read More
image for news Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Lilly declares third-quarter 2025 dividend
LLY
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral

INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.

Read More
image for news Lilly declares third-quarter 2025 dividend
Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript
LLY
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Neutral

Eli Lilly and Company (NYSE:LLY ) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey Emmick - Vice President of Diabetes Product Development Kenneth L Custer - Executive VP & President of Lilly Cardiometabolic Health Michael Czapar - Director of Investor Relations Ruth Gimeno - Corporate Participant Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Bryan Russell Dollinger - Leerink Partners LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.

Read More
image for news Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
LLY
Published: June 22, 2025 by: PRNewsWire
Sentiment: Neutral

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS , June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used …

Read More
image for news Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Final Trade: LLY, SHEL, USO, WMT
LLY, WMT
Published: June 20, 2025 by: CNBC Television
Sentiment: Neutral

The final trades of the day with the Fast Money traders.

Read More
image for news Final Trade: LLY, SHEL, USO, WMT
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
LLY
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
LLY
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

Read More
image for news What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
LLY, SRRK
Published: June 18, 2025 by: Benzinga
Sentiment: Positive

Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.

Read More
image for news Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
LLY, VERV
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

Read More
image for news Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
LLY
Published: June 17, 2025 by: Fast Company
Sentiment: Positive

Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.

Read More
image for news Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV
LLY
Published: June 17, 2025 by: Schwab Network
Sentiment: Negative

Breaking news hits Morning Trade Live with JetBlue (JBLU) cutting back flights after it reported weaker travel demand. Diane King Hall talks about the report and shares how it differs from its airline peers.

Read More
image for news JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV
PFE or LLY: Which Is the Better Value Stock Right Now?
LLY, PFE
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?

Read More
image for news PFE or LLY: Which Is the Better Value Stock Right Now?
Want a $1 Million Retirement Portfolio? Invest $100,000 in These 3 Stocks and Wait 10 Years
LLY, PLTR, SHOP
Published: June 16, 2025 by: 24/7 Wall Street
Sentiment: Positive

Key Points in This Article: Growing a $100,000 investment into a $1 million retirement portfolio in 10 years requires a 25.9% CAGR from high-growth stocks with solid financials.

Read More
image for news Want a $1 Million Retirement Portfolio? Invest $100,000 in These 3 Stocks and Wait 10 Years
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
LLY
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.

Read More
image for news Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
LLY
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive

LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.

Read More
image for news Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Drug pricing reform talks with US government lack clarity, industry executives say
LLY, MRK
Published: June 10, 2025 by: Reuters
Sentiment: Neutral

Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday.

Read More
image for news Drug pricing reform talks with US government lack clarity, industry executives say
Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
LLY
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor Relations Conference Call Participants Unidentified Analyst Get started here.

Read More
image for news Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?
LLY, NFLX, V
Published: June 09, 2025 by: 24/7 Wall Street
Sentiment: Neutral

Justin Sullivan / Getty Images Visa Fintech is changing the world and Visa is at the center of it.

Read More
image for news Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
LLY
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Read More
image for news Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Rare Outflow Signals Hit Eli Lilly Shares
LLY
Published: June 06, 2025 by: FXEmpire
Sentiment: Neutral

“Buy low, sell high” is a common investing mantra. It's easy to understand, but often hard to execute because emotion gets in the way.

Read More
image for news Rare Outflow Signals Hit Eli Lilly Shares

About Eli Lilly and Company (LLY)

  • IPO Date 1972-06-01
  • Website https://www.lilly.com
  • Industry Drug Manufacturers - General
  • CEO David A. Ricks
  • Employees 47000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.